Your Reporter Kelly Werthmann specializes in coverage of Aurora. She also anchors CBS Colorado's weekend evening newscasts. Share you story ideas with her by sending an email to yourreporter@cbs.com.

AURORA, Colo. (KDVR) — Ross Camidge is the director of the Thoracic Oncology Department at the University of Colorado Cancer Center. The doctor, who has an MD and Ph.D, has helped treat thousands of ...

In his 20-year research career in Colorado, University of Colorado Cancer Center member D. Ross Camidge, MD, PhD, has published nearly 400 academic papers. But perhaps none have been so personal to ...

A study led by D. Ross Camidge, MD, Ph.D., director of thoracic oncology at the University of Colorado School of Medicine and CU Cancer Center member, has helped to define MET amplification as a rare ...

D. Ross Camidge, director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses the development of brigatinib, an oral inhibitor of anaplastic lymphoma kinase (ALK). D.

D. Ross Camidge, director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses the need for more research into brain metastases in lung cancer patients. D. Ross Camidge ...

Brigatinib (Alunbrig) continued to prove its value as a promising first-line treatment for ALK-positive non-small cell lung cancer (NSCLC), according to a second interim analysis of the ALTA-1L trial.

A study led by D. Ross Camidge, MD, PhD, director of thoracic oncology at the University of Colorado School of Medicine and CU Cancer Center member, has helped to define MET amplification as a rare ...